Abionyx bullish on acute kidney injury drug's prospects

French biotech Abionyx Pharma (Euronext: ABNX) has reported that the pilot Phase IIa trial of CER-001 as a treatment for septic patients at high risk of developing acute kidney injury (AKI) met its primary objective.

Secondary endpoints were also met in the RACERS study, the goal of which was to investigate whether the use of CER-001 at different doses, in combination with standard of care treatment, is safe and effective, and to establish safety and tolerability of the dosage regimens in order to select the optimal dose.

"The broad pleiotropic effect of our apoA-I bioproduct can target multiple facets of septic disease"Loreto Gesualdo, head of the Nephrology, Dialysis and Transplantation Unit, University of Bari Aldo Moro, Italy, and lead investigator of the RACERS study, said: “There is a complete lack of treatment options for septic patients at high risk of developing AKI, a disease that in 2019 had an estimated 13.7 million related deaths globally.